Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo - sprookjes - yvandenbroek - TriplyDB

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

http://www.wikidata.org/entity/Q33919548

about

Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.Parkinson's disease: animal models and dopaminergic cell vulnerability The relationship between the dopaminergic system and depressive symptoms in cervical dystonia Presynaptic effects of levodopa and their possible role in dyskinesia.Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity Effect of olfactory manganese exposure on anxiety-related behavior in a mouse model of iron overload hemochromatosis.Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.A new knock-in mouse model of l-DOPA-responsive dystonia.Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts hVMAT2: A Target of Individualized Medication for Parkinson's Disease.Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.Parkinson's Disease: From Pathogenesis to Pharmacogenomics Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy.Early Paradoxical Increase of Dopamine: A Neurochemical Study of Olfactory Bulb in Asymptomatic and Symptomatic MPTP Treated Monkeys.Superoxide Dismutase (SOD)-mimetic M40403 Is Protective in Cell and Fly Models of Paraquat Toxicity: IMPLICATIONS FOR PARKINSON DISEASE.Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Dopamine depleters in the treatment of hyperkinetic movement disorders.Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence.Selective Enhancement of Dopamine Release in the Ventral Pallidum of Methamphetamine-Sensitized Mice.Alteration to Dopaminergic Synapses Following Exposure to Perfluorooctane Sulfonate (PFOS), in Vitro and in Vivo.Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress.Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.Prenatal nicotine exposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice.U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells.Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules.Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate.The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease.

P2860

Q27308109-5F2EECED-4C4B-491A-8262-85B7BA682C34 Q28080503-1D1358EB-D313-4F4B-83F5-19333E2D7957 Q33841496-DA2DB79B-8E94-4F57-BAD2-8E2481B75E73 Q35040280-D2D79ABB-8A30-42FE-BA25-39BC5D93A2CB Q35172603-81D6E2B7-901F-4FD1-BAE5-EF58280AEE71 Q35775723-C040C716-014E-4AB9-A109-D59620EB240F Q35810975-EDAD92FF-1793-47DD-B8E7-BFD8F76CB48D Q35908873-A23D91D0-25E3-4A34-A3CB-09E53EA44541 Q35999331-A283A789-C21D-4B62-A067-55825FBB5243 Q36232197-F524D502-059B-47ED-8D77-CBC029D96B32 Q36559682-38D4D3A2-0564-4245-A03B-A45B3365E116 Q36691830-6FA63F9A-021E-479A-BF4B-91623EE0160C Q36817270-A25E38FD-5217-42F0-A5EF-9688C349BC44 Q37136467-D521FBB8-FE61-4252-A0F2-73C24F68811B Q37701053-4D128B2C-A901-407E-9194-357BAC1FF1F2 Q37711589-4A94C030-7529-469B-AFCA-B29BFBBFED7A Q37729129-BF137D60-1AA4-4F5B-AF12-C0D39F59640A Q37736100-D00CD58D-338D-4373-8B74-7B83B0B44CF7 Q38287948-537DA4A9-DB4E-4A22-85B6-A7B7497ABF1F Q38787990-EB98018C-7854-4FE6-B465-267F0E641B16 Q38809645-FB44702A-F3DF-43E3-9A33-CC08856E8D25 Q38926644-A40F1271-0A16-4BB8-9ECB-D20E7DFC80A0 Q39000590-28F360E9-83B9-486D-930C-54062BA1FD69 Q40108542-2DDC17CA-D962-4AA6-B001-A611192D5681 Q41031814-3FE9EC6B-D05C-46C3-A651-1A470CC1FD4E Q41379166-8AF7B2C4-7D6C-4792-A344-7099670D37D6 Q41524173-4F9E20EC-0B38-4DDC-91C1-185A8627ECA4 Q42705599-5E935F6A-5340-443A-A689-6E6535C4558F Q46305258-09FB969D-5777-4E50-BCBB-282B807E3AFA Q47258034-22B66ABF-23A8-4E7E-A901-A5F3D441BB60 Q47616782-337A7FD9-1CDF-4A93-ABF3-10D689A570B7 Q47759449-086B241A-CD02-4A4E-A86B-0854EEADFEFB Q48250429-B8F41CCC-76C5-44EC-B150-7BC758F846DD Q48277596-44CAE18F-565D-47B6-B7A4-A3F67B5B4F59 Q48433008-F304F2A7-ABC7-4129-B8FD-B7D39D9C43E6 Q48585249-995B6D61-2D20-41C9-9DF0-2B01684C33AA Q50198345-401EB4C3-C0F2-4566-BC11-A4A26DE8146C Q52624714-8A5A164F-CE92-439E-A24A-1452EE893528 Q52632229-502769A0-5038-4C65-B13F-C4A1E9AF3B9E Q54994816-9FAE6AEF-DAB0-4B25-BAAB-C1AF1194DCEF

P2860

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

http://www.wikidata.org/entity/Q33919548

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@ast

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@en

type

label

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@ast

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@en

prefLabel

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@ast

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@en

P1433

Q33919548-BAE3A4CF-2F4D-4B85-9321-5357FC5C7C6F

P1476

Q33919548-3A4DB494-747D-473F-82B1-0984D38CBE89

P2093

Q33919548-285B9062-21F8-4C46-9568-AD098EC4E6E5

Q33919548-5A3C1162-04CA-4450-B826-A9B9D72E249C

Q33919548-5D22CC96-6407-43AE-A1E6-F7BEF7DAD82C

Q33919548-683BB19B-A030-40BB-AA31-1F6B106EDF79

Q33919548-6D658FE4-D39C-4D2F-9B1A-4F19C8CBB556

Q33919548-872CF6B4-1EFB-4D07-B4FD-EB3AA0111B6C

Q33919548-AEDEA4EC-AFC5-4D0B-821B-5649E78DF3AC

Q33919548-C6BB3AA6-48DD-4426-A3BE-679FA2E2713F

Q33919548-CF7FD6A3-B518-49B8-8872-2CF5219D2016

Q33919548-D59CF6CF-DE32-4450-B977-58CD8BD64DCC

P2860

Q33919548-00983E6F-354C-4195-88FC-A2CD5F1C46C6

Q33919548-04BF9F6D-FAA6-486F-971E-621E1CDF597D

Q33919548-0DD02498-6D75-4678-AEC6-F4E84E9963EB

Q33919548-0E556C63-3FD6-4179-9DAE-5545BD1C4753

Q33919548-1004F561-E265-46D1-9B25-839B6CABDB93

Q33919548-1160176F-2677-4186-AE49-B2568A81A57C

Q33919548-131437EA-54EE-49EB-9664-1207DE93CCDD

Q33919548-1328A17B-B80D-4AC9-A3EB-3F2A717ED931

Q33919548-1615C8DF-1D16-4AA1-AAF4-E511D828DFFC

Q33919548-1652BB94-E5BD-4176-AF2A-A96E3A1202FF

P304

Q33919548-3CDFE5D3-88E9-405C-9A6C-15DF1F18A5EA

P31

Q33919548-375B6100-D4E0-4232-A7D2-9FF33E180158

P356

Q33919548-DF06BF8C-9AC7-4A44-9B09-D524024DD784

P407

Q33919548-0D27F69E-0897-4051-80B6-C88300B3EEBD

P433

Q33919548-4FDE6E62-D90D-4D9A-BAC5-018D24BBDD3D

P478

Q33919548-CFED2CDB-8A2E-4253-AF4C-EB8C256E4B2F

P50

Q33919548-06EA3877-3F7F-4965-A662-451AA13627BB

Q33919548-0FB5BFFE-FE7E-43F4-9EA3-E83B3A55D10D

Q33919548-E722E4BD-F5EA-4ED1-A57E-60D064FC2DD6

Q33919548-EDEDF9EA-9573-40E1-8C33-C54C0D300210

Q33919548-FA774AAA-8108-4949-9C4C-009201D3ECCF

P577

Q33919548-AC137CAA-6E0F-47AE-88A1-E8779A2D3D3C

P5875

Q33919548-0164B3A1-3A97-4C12-9258-1102924BB2A3

P698

Q33919548-BCF4FFA7-AE6E-4C58-BB00-DA2C745DD2F1

P921

Q33919548-07EB78C8-A8CC-4B62-9FD1-67599EAE7E29

P932

Q33919548-2D79DF55-C1F2-442B-A4F2-3B67D73B231D

P356

PNAS.1402134111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Increased vesicular monoamine ...... ated neurodegeneration in vivo

@en

P2093

Ali Salahpour

http://www.w3.org/2001/XMLSchema#string

Carlos R Lazo

http://www.w3.org/2001/XMLSchema#string

David S Goldstein

http://www.w3.org/2001/XMLSchema#string

Ellen J Hess

http://www.w3.org/2001/XMLSchema#string

Hong Yi

http://www.w3.org/2001/XMLSchema#string

Kelly M Lohr

http://www.w3.org/2001/XMLSchema#string

Minzheng Wang

http://www.w3.org/2001/XMLSchema#string

Shawn P Alter

http://www.w3.org/2001/XMLSchema#string

Thomas S Guillot

http://www.w3.org/2001/XMLSchema#string

Xueliang Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Intraneuronal dopamine-quinone synthesis: A review

Expression cloning of a reserpine-sensitive vesicular monoamine transporter

The molecular neurobiology of depression

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

Functional identification and molecular cloning of a human brain vesicle monoamine transporter

Brain dopamine-serotonin vesicular transport disease and its treatment

Vesicular integrity in Parkinson's disease

VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter

Animal models of neuropsychiatric disorders

P304

9977-9982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1402134111

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Alison I Bernstein

Laura M Vecchio

Kristen A Stout

P577

2014-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263550564

http://www.w3.org/2001/XMLSchema#string

P698

24979780

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4103325

http://www.w3.org/2001/XMLSchema#string